cyrilzakka/clinical-trials huggingface dataset:
Self-Management Support for Lung Cancer Patients With Cachexia

The goal of this randomized clinical trial is to test the efficacy of self-management support based exercise combine nutrition intervention in lung cancer patient with cancer cachexia anorexia syndrome . The main question it aims to answer is:

• Would exercise combine nutrition intervention improve lung cancer patients' nutrition status? Participants will make custom exercise plan and eat enough protein food after self-management support based education.

And there is a comparison group: Researchers will compare comparison group to see nutrition status who receive routine health education.


Eligibility Criteria:
Inclusion Criteria:

1. Diagnosed lung cancer(ICD-10 code: C33-C34)
2. Body weight loss: body weight loss 2% before recruitment 2 months or body weight loss 5% before recruitment 6months.
3. Physician judged may do home exercise without supervisor.
4. Has smart phone and agree to use exercise associated application.
5. Agree to wear Xioami smart band as long as passible.
6. Conscious clear and communication.
7. Eastern Cooperative Oncology Group (ECOG) 0-1.

Exclusion Criteria:

1. Participants with cardiovascular disease can't exercise without supervisor.
2. Diabetes Mellitus with blood sugar poor control.
3. Chronic obstructive pulmonary disease with dyspnea on exertion.
4. Platelets \< 50000mm3 due to disease or treatment.
5. Hemoglobin \<10mg/dl.
6. Recently stumble, severe pain, cognitive and behavior change.
7. Suspect or diagnosed brain metastasis.
8. Suspect or diagnosed bone metastasis.
9. Receive Nasogastric tube feeding or parenteral nutrition.
10. Physician judged can't do home exercise.
Comprehensive Management for the Treatment of Obstructive Sleep Apnea

Study objetives : The aim of this study is to assess the impact of a combined therapy treatment (physical exercise, oropharyngeal exercises and dietary recommendations) on symptoms and quality of life in patients with OSAS, as an alternative or addition to therapeutic treatment with nocturnal CPAP.

The obstructive sleep apnea syndrome (OSAS) is characterized by repetitive obstruction of the upper airway during sleep. OSAS is associated with a wide range of health consequences such as daytime sleepiness, cognitive impairment and metabolic and cardiovascular diseases. In Spain the prevalence of this disease is 3 to 6%, constituting a public health problem. The recommended first line treatment for OSAS is continuous positive pressure airway (CPAP).

Physical exercise has been shown to ameliorate the consequences of OSAS such as cardiovascular disease, glucose intolerance and fatigue. Scientific studies have shown that vigorous physical activity is associated with a decrease in the prevalence of OSAS, improved sleep efficiency and the Epworth Sleepiness Scale.

Moreover, recent evidence has shown that oropharyngeal exercises can be useful in the treatment of OSAS decreasing neck circumference, snoring, subjective sleepiness and AHI as well as improving the quality of life and saturation oxygen.

The 60-70% of patients with OSAS is overweight or obese showing that a high body mass index (BMI) is an independent risk factor for the occurrence of OSAS. Many studies have shown that weight loss is associated with significant reduction in AHI.

However, despite the scientific evidence to justify the inclusion of these modalities, there is no study that has analyzed the impact of performing together all these interventions. It is expected that the combination can produce a cumulative effect that impacts significantly on improving indicators of OSAS.

The investigators will include patients with a recent diagnosis of moderate or severe OSA. Patients will be randomized to interventional or control group.

Patients included in the study will be followed for almost three months and they will be examined at baseline and after time of follow-up or intervention.

Eligibility Criteria:
Inclusion Criteria:

* Moderate to severe Obstructive Sleep Apnea Hypopnea Syndrome (AHI \> 15/h)

Exclusion Criteria:

* BMI \> 40
* Concomitant heart disease, stroke or severe neuromuscular with medical judgment not doing exercise.
* Musculoskeletal disorders that impede the realization of the exercises
* Sleepiness affects your physical or occupational functioning.
Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C

The purpose of this study is to evaluate the efficacy and safety of telaprevir in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV) in treatment-experienced Black/African American and non-Black/African American participants with Genotype 1 Chronic Hepatitis C (CHC), who have not achieved a sustained viral response with a prior course of interferon-based therapy.

This is a single-arm, open-label, multicenter study of treatment-experienced participants with Genotype 1 CHC, who self-identified as Black/African American (Group A) or who did not self-identify as Black/African American (Group B). Participants did not achieve a sustained virologic response 24 weeks after at least 1 prior course of Peg-IFN-alfa-2a/RBV therapy of standard duration, and have 1 of the following viral responses:

* Prior relapse: Participant had a documented undetectable hepatitis C virus ribonucleic acid (HCV RNA) level at the planned end of treatment of at least 42 weeks duration (HCV RNA evaluated anytime between 3 weeks before and 6 weeks after the last dose of Peg IFN-alfa-2a or RBV).
* Prior null response: Participant had a \<2-log10 decrease in HCV RNA at 12 weeks, during prior Peg IFN-alfa-2a/RBV treatment, but never achieved undetectable HCV RNA while on treatment.
* Prior partial response: Participant had a \>=2-log10 decrease in HCV RNA at 12 weeks, during prior Peg IFN-alfa-2a/RBV treatment, but never achieved undetectable HCV RNA while on treatment.

Eligibility Criteria:
Inclusion Criteria:

* Participants self-identify as Black/African American (Group A) or did not self-identify as Black/African American (Group B)
* Participants have Genotype 1 CHC and laboratory evidence of hepatitis C virus (HCV) infection for at least 6 months
* Participants did not achieve sustained viral response 24 weeks after last dose of study drug (SVR24), after at least 1 prior course of Peg-IFN-alfa-2a/RBV therapy of standard duration

Exclusion Criteria:

* Participants have received previous treatment with telaprevir or any other protease inhibitor(s) for CHC
* Participants who have evidence of hepatic decompensation
* Participants have diagnosed or suspected hepatocellular carcinoma
* Participants have any other cause of significant liver disease in addition to HCV
* Participants are currently abusing illicit drugs or alcohol, or have history of illicit substance or alcohol abuse within 2 years before the screening visit
* Participants who participated in any investigational drug study within 90 days before dosing
A Study to Evaluate Alzheimer's Disease Conversion Rate Differences Between High-risk Mild Cognitive Impairment (MCI) and Low-risk MCI in a Real World Setting

This study will be conducted to evaluate the rate of Alzheimer's disease conversion differences between high-risk mild cognitive impairment (MCI) and low-risk MCI.


Eligibility Criteria:
Inclusion Criteria:

* Participant over 55 years old and less than 90 years old
* Participant with subjective memory complaint by informant
* Clinical Dementia Rating (CDR) of 0.5; memory score box must be at least 0.5
* General cognition and functional performance sufficiently preserved such that a diagnosis of Alzheimer's disease cannot be made by the site physician at the time of the screening visit
* Essentially preserved activities of daily living
* Absence of dementia
* Participant with Seoul Neuropsychological Screening Battery-Dementia Version cut-off score between 134.25 and 188.25
* Participants and caregivers who give written authorization to use their personal and health data
* Cognitive decline history within past 6 months from the baseline

Exclusion Criteria:

* Diagnostic evidence of probable Alzheimer's disease consistent with National Institute of Neurological and Communicative Diseases and Stroke-Alzheimer's Disease and Related Disorders Association
* CDR-Global score (CDR-GS) \>1
* Participant who has taken memantine, acetylcholinesterase inhibitors, or nootropics prior to participating in this study
* Any significant neurologic disease: other than suspected incipient Alzheimer's disease, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities
* Neuroimaging: participant with severe subcortical hyperintensities: D3-P3
* Magnetic resonance imaging exclusions: presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body
* Participant who is pregnant, lactating or of childbearing potential (i.e., women must be two years post-menopausal or surgically sterile)
Rhinitis in the Elderly: The Role of Vitamin D

A study of the role of vitamin D in elderly subjects with perennial and/or nonallergic rhinitis. The hypothesis is that vitamin D supplementation will improve rhinitis symptoms and rhinitis related quality of life.

Rhinitis in the elderly is poorly understood as this group of patients has been ignored in almost all rhinitis studies. Vitamin D deficiency and insufficiency are very common, especially in the elderly. Vitamin D may play an important role in respiratory disease as shown by studies in asthma. This is a randomized, double-blind, placebo controlled, cross-over study. The investigators will look for the effect of vitamin D 4,000 I.U/day vs. placebo for six weeks on symptom scores and rhinitis related quality of life. This study will be performed in the period Nov. 1, 2013 and March 31, 2014, to try to avoid seasonal fluctuations of serum vitamin D due to sun exposure. The investigators will also look for possible associations between serum vitamin D at baseline and study subjects demographics, treatment, and symptom scores.

Eligibility Criteria:
Inclusion Criteria:

* Subjects 65 years old and older with perennial and/or nonallergic rhinitis

Exclusion Criteria:

* Current smokers, digoxin, liver disease, anticoagulants (except for aspirin), planning a surgical procedure during the study period.
A Study of the Expression of Nogo and Reticulon Genes in Skeletal Muscle of Patients With Amyotrophic Lateral Sclerosis

This is a study of the expression of nogo and reticulon genes in the skeletal muscle of patients with amyotrophic lateral sclerosis (ALS).


Eligibility Criteria:
Inclusion Criteria:

* Patients with definite ALS
* Males or females
* Age \> 18

Exclusion Criteria:

* Patients with other neuromuscular affections
Magnet for Corneal Foreign Bodies

This is a prospective, interventional study to assess the effectiveness and safety of a commercially available "eye magnet" to remove corneal foreign bodies.

The vast majority of corneal foreign bodies are metallic and thus are frequently ferromagnetic. Consequently, it may be possible to use a magnet to remove most corneal foreign bodies. There are commercially available products for removing corneal foreign bodies, but there are no published studies assessing these devices.

This will be a prospective interventional study to assess the use of an eye magnet for the removal of metallic corneal foreign bodies in the emergency department.

After the patient signs written, informed consent, the physician will attempt to remove the corneal foreign body with the North by Honeywell 326734G Eye Magnet with Loop. If the physician is unable to remove the corneal foreign body with the magnet, he or she may proceed with standard care.

The treating physician will fill out a brief data collection form for each patient to track various outcomes as discussed below.

Eligibility Criteria:
Inclusion Criteria:

* present to the emergency department with a metallic corneal foreign body

Exclusion Criteria:

* prisoners
* pregnant women
* have pacemakers or metallic facial implants
* possible globe rupture
The Multitasking Rehabilitation She Enhanced Walking Speed Compared to the Simple Post Stroke Rehabilitation Task (AVC)?

Stroke is the leading cause of severe disability in adults. The first cause of alterations in the quality of life and autonomy in these patients are disorders of walking and the balance. They are the leading cause of falls responsible for important medical, surgical and economic complications as well as a reactionary social isolation.

The techniques of rehabilitation of walking to the subacute phase of a stroke are usually based on automatic walking.Off walking is a complex activity usually performed in everyday life in association with multiple tasks. It is therefore interesting to re-educate walking in dual task or even in multitasking.


Eligibility Criteria:
Inclusion Criteria:

* Major: age between 18 and 90 years
* Hospitalized for ischemic or hemorrhagic hemispheric stroke confirmed by CT or MRI \<6months
* walking disorder with the possibility of walking 10 meters with or without technical assistance (speed \<1.2m / s)
* verbal understanding with complex orders
* Affiliates to social security

Exclusion Criteria:

* Brainstem stroke or cerebellar
* Hypoacusia annoying understanding
* Visual gene embarrassing awarding
* severe aphasia: no understanding of complex orders
* neurological or musculoskeletal history affecting walking
* Participation in interventional research protocol in motor rehabilitation of the lower limb or cognitive
* Patient under guardianship or deprived of liberty
* pregnant women, parturient women or lactating (art L.1121-5)
Growth Hormone Resistance of Beta-cells

The purpose of the research study is to better understand how beta-cells (cells in the pancreas that make insulin and help regulate blood sugar) respond to growth hormone in people with a personal history of gestational diabetes (high blood sugar in pregnancy) at the University of Missouri. The aim of the study is to advance understanding of how growth hormone affects beta-cells and risk factors for developing gestational diabetes and type 2 diabetes.


Eligibility Criteria:
Inclusion Criteria:

* Singleton, full term pregnancy within the past 5 years
* Hemoglobin HbA1c ≤5.6% and fasting blood glucose \<100 mg/dl
* Body mass index ≥30.0 kg/m2 and \<45.0 kg/m2, because the majority of women with GDM have overweight/obesity

Group specific inclusion criteria:

* Gestational Diabetes Group: History of gestational diabetes in the most recent pregnancy
* Control Group: no history of gestational diabetes

Exclusion Criteria:

* Pregnant, planning to become pregnant during the study, or breastfeeding
* Current diagnosis or history of type 1 or type 2 diabetes
* Use of medications that can impact the study outcomes (e.g., GLP-1 receptor agonists)
* History of bariatric surgery
* Known hypothyroidism or use of thyroid medications
* History of intracranial hypertension, including papilledema, or a condition that increases the risk of developing intracranial hypertension, such as Turner Syndrome, Prader-Willi Syndrome, or renal impairment
* Current cancer or cancer that has been in remission less than 5 years
* First degree relative with diabetes diagnosis
* Evidence of significant anemia or significant end organ dysfunction (e.g., liver, kidney, heart disease)
* Alcohol use disorder, use of controlled substances, or smoking \>2 cigarettes per day
* Greater than 3% weight loss within three months of screening or engaged in regular (≥3 days per week), continuous moderate- or high-intensity exercise of ≥30 min duration
* Mentally disabled persons, prisoners, and persons with inability to grant voluntary informed consent
Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA™ in HIV Patients

Primary Objective:

- To evaluate the effect of single and repeated administration of rifapentine given as daily or weekly regimen on steady-state pharmacokinetic parameters of efavirenz, emtricitabine and tenofovir given as a fixed dose combination (ATRIPLA™ ).

Secondary Objective:

- To evaluate the safety and tolerability of concomitant administration of rifapentine and ATRIPLA™ given to HIV+ patients

* Screening to admission: up to 21 days
* Admission to the end of the follow-up: up to 41 days

  * Period 1: Treatment period of 15 days with ATRIPLA™ (background therapy). Patients should receive the same regimen and dose of ATRIPLA™ during the all study screening and period 1.
  * Period 2: Treatment over a period of 21 days in co-administration with rifapentine.
  * Follow up: 3 to 5 days after the last rifapentine administration.

Eligibility Criteria:
Inclusion criteria :

- HIV+ male and female patients receiving ATRIPLA™ aged 18 to 55 years old with a CD4 count cells of at least 350

Exclusion criteria:

* Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, haematological (patients with porphyria), neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynaecologic (if female), or infectious disease, or signs of acute illness other than HIV disease.
* Active or latent tuberculosis infection

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Pap Smear Collection With the Papette Brush

This research study is comparing Pap smear collection techniques using the Papette brush to traditional spatula and cytology brush for cervical cancer screening

At the investigators institution the investigators have been using both the traditional spatula and cytology and the Papette brush for Pap smear collection. The investigators will be comparing adequacy of sample rates, provider perceived pain and bleeding and overall satisfaction with each collection technique.

Eligibility Criteria:
Inclusion Criteria:

* Adult women, aged 21-64 years old.
* Have given consent for medical records to be accessed.
* Who will have a Pap smear exam in CIM from July 2021 through June 2022.

Exclusion Criteria:

* Women, age \< 21 or \> 64.
* Has vaginal spotting present during cervical sampling.
* Did not give consent to have medical records accessed.
A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma

This study will evaluate the efficacy and safety of MabThera/Rituxan (rituximab) in treatment-naive patients with non-bulky follicular non-Hodgkin's lymphoma. The anticipated time on study treatment is 3 months.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients 18-75 years of age
* Newly diagnosed non-bulky follicular non-Hodgkin's lymphoma
* \>/=1 measurable lesion
* No prior treatment (no corticosteroids or radiotherapy)

Exclusion Criteria:

* Transformed follicular lymphoma
* Cerebral or meningeal lymphomaotus localization
* Uncontrolled concurrent infection
Ketamine Versus Etomidate During Rapid Sequence Intubation: Consequences on Hospital Morbidity

The expected benefit is a reduction of the morbidity of patients admitted in the intensive care unit having received ketamine for intubation.

The national recommendations of sedation concerning the intubation in emergency settings advise the use of a hypnotic, etomidate associated to succinylcholine. A national inquiry showed that more than 80% of prehospital intubations use a rapid sequence intubation as sedation. However, several recent studies throw into question the use of etomidate in this indication. Indeed, etomidate is a powerful inhibitor of the synthesis of cortisol. Adrenocortical hormone insufficiency is clearly associated to an increase in the morbidity-mortality of critically ill patients. Several authors advise therefore against the use of etomidate for such patients. Yet, to date, only indirect arguments associating the use of etomidate with excessive morbidity-mortality exist. A real causality link is not yet established. Another hypnotic that could constitute a therapeutic alternative to the use of etomidate exists: ketamine. The advantage of this molecule is that it does not inhibit the adrenocortical hormone axis.

Objectives: To evaluate sedation using ketamine versus etomidate in term of morbidity-mortality in critically ill patients intubated in the prehospital setting.

Experimental diagram: A prospective, multicentric, randomized, controlled, simple blind trial with independent analysis of the primary outcome.

The expected benefit is a reduction of the morbidity of patients admitted in the intensive care unit having received ketamine for intubation. The risks incurred for patients being suitable to this research are bound essentially to the adverse effects of ketamine. These include some psycho-dyslectic manifestations: nightmare, unpleasant awakening, and disruption of the visual, auditory sensations and mood, a sensation to float and sometimes depersonalization. These adverse effects are warned by a continuous administration of benzodiazepines.

Eligibility Criteria:
Inclusion Criteria:

* Patient requiring sedation for prehospital endotracheal intubation
* Age ≥ 18 years
* Consent of a family member if present, then of the patient for the pursuit of research

Exclusion Criteria:

* Patient in cardiac arrest
* Presence of contraindication to succinylcholine:

  * Personal or familial history of malignant hyperthermia
  * Known hypersensitivity to succinylcholine
  * Skeletal muscle disease
  * Myasthenia
  * Known hyperkalemia
  * Severe ophthalmic injury
  * Known congenital deficit in plasmatic pseudo-cholinesterase
* Presence of contraindication to ketamine:

  * Known hypersensitivity to ketamine
  * Known porphyria
  * Severe hypertension
* Presence of contraindication to etomidate:

  * Known untreated adrenal insufficiency
  * Known hypersensitivity to etomidate
* Known pregnancy
* Unaffiliated patient to the social insurance
Antibiotics After Breast Reduction:Clinical Trial With Randomization

This study was designed to determine the role of antibiotics reduction mammaplasty influence surgical site infections rates.

Prevention of SSI is important due to its morbidity, longer hospital stays and higher costs. In many surgical procedures where the risk of infection is relatively low and the postoperative infection can be treated properly, the role of antibiotics is not clear.

Despite the lack of evidence from prospective randomized controlled trials of evaluation, the use of antibiotics in plastic surgery is widespread in order to offer the highest safety standards patients.

The breast reduction is defined as "clean surgery" with a lower infection rate to 3.4%. Thus, the antibiotic is not recommended. However, studies have shown a real rate of infection associated with procedures ranging from 4-36%.

Thus, this trial was designed to verify the role of antibiotics in reduction mammaplasty.

Eligibility Criteria:
Inclusion Criteria:

* Breast hypertrophy
* Body mass index between 19 to 30 kg/m2

Exclusion Criteria:

* Patients undergoing a surgical procedure in the breast
* Diagnosis of breast pathology
* Smoking
* Childbirth or lactation less than a year
* Uncontrolled comorbidities
* Use of immunosuppressive drugs
* Misuse of capsules supplied
* Absence during the weekly follow-up